With online doctor quiz, edugaming dons lab coat

Share this article:
Stephen Smith
Stephen Smith

Could an online quiz be the future of continuing medical education? In a twist on the “edu-gaming” phenomenon, Cleveland Clinic and physician site MDLinx aim to answer that question with The Smartest Doc, a daily one-minute quiz that aims to keep doctors up to date on the medical literature by appealing to their competitive spirit.

Cleveland Clinic furnishes content for the multispecialty quiz, which consists of five or fewer questions and is scored based on speed and accuracy. Participants can view leader boards showing where they've placed regionally and nationally.

“Some physicians have chosen to make teams,” said MDLinx's Stephen Smith. “Some use it as a more local competition. If you're an oncologist in Omaha, you can play the quiz, then when you talk to each other you have bragging rights.”

Physicians can see the correct answer to any question they get wrong and a couple clicks takes them to a full CME course on the topic from Cleveland Clinic.

Tailored to internists, family physicians, oncologists, pediatricians, diabetes experts and neurologists, the quiz is ad supported, and MDLinx will entertain sponsorships by pharmas, whether of the online quiz by specialty or for exhibit booths at national meetings of medical societies, where the quiz could serve as a lure, drawing physician foot traffic.

Other ventures, including QuantiaMD and some medical journals, have run quizzes, but Smith said MDLinx's quiz is distinguished by its daily schedule and competitive element.

“It's every day, and after a month, participants will have been exposed to the most current literature and best practices,” said Smith, who is chief marketing officer of MDLinx parent M3.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...